Primary and Secondary Prevention Strategies for Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device: A Systematic Review and Network Meta-analysis.

[1]  V. Kaul,et al.  Su1395 INITIATION OF DANAZOL IN LEFT VENTRICULAR ASSIST DEVICE PATIENTS WITH RECURRENT GI BLEEDING LEADS TO SHORTER HOSPITAL STAYS AND FEWER BLOOD TRANSFUSIONS , 2019, Gastrointestinal Endoscopy.

[2]  D. Taber,et al.  Effect of Angiotensin II Inhibitors on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices. , 2019, Journal of the American College of Cardiology.

[3]  D. Burkhoff,et al.  Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device , 2018, Circulation. Heart failure.

[4]  Snehal R. Patel,et al.  Digoxin Is Associated With a Decreased Incidence of Angiodysplasia-Related Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Devices , 2018, Circulation. Heart failure.

[5]  E. Rajan,et al.  Danazol treatment of gastrointestinal bleeding in left ventricular assist device-supported patients. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  D. Burkhoff,et al.  Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device. , 2018, Journal of cardiac failure.

[7]  Sahil Agrawal,et al.  Thirty-Day Readmissions After Left Ventricular Assist Device Implantation in the United States: Insights From the Nationwide Readmissions Database , 2018, Circulation. Heart failure.

[8]  N. Uriel,et al.  Multicenter Evaluation of Octreotide as Secondary Prophylaxis in Patients With Left Ventricular Assist Devices and Gastrointestinal Bleeding , 2017, Circulation. Heart failure.

[9]  T. Tan,et al.  Novel Use of Thalidomide in Recurrent Gastrointestinal Tract Bleeding in Patients with Left Ventricular Assist Devices: A Case Series. , 2017, Heart, lung & circulation.

[10]  T. Tan,et al.  Novel Use of Low-dose Thalidomide in Refractory Gastrointestinal Bleeding in Left Ventricular Assist Device Patients , 2017, The International journal of artificial organs.

[11]  R. Malhotra,et al.  Tolerability and Biological Effects of Long-Acting Octreotide in Patients With Continuous Flow Left Ventricular Assist Devices , 2017, ASAIO journal.

[12]  S. Russell,et al.  Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  M. Guglin,et al.  Danazol as a Treatment to Reduce Reoccurrence of Hospitalization for Gastrointestinal Bleeding in Patient with Continuous Flow Left Ventricular Assist Device , 2016 .

[14]  J. Bauditz.  Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations. , 2016, World journal of gastroenterology.

[15]  J. Baumwol,et al.  The Use of Octreotide to Treat Refractory Gastrointestinal Bleeding in Patients Supported With a Continuous-Flow Left Ventricular Assist Device , 2015 .

[16]  J. Kirklin,et al.  Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. , 2015, ASAIO journal.

[17]  A. Guha,et al.  Gastrointestinal bleeding after continuous-flow left ventricular device implantation: review of pathophysiology and management. , 2015, Methodist DeBakey cardiovascular journal.

[18]  Robert J. Huang,et al.  GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. , 2014, Gastrointestinal endoscopy.

[19]  N. Meader,et al.  A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation , 2014, Systematic Reviews.

[20]  R. Contri,et al.  Current indications for heart transplantation and left ventricular assist device: a practical point of view. , 2014, European journal of internal medicine.

[21]  Mark Loeb,et al.  Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments , 2014, BMC Medical Research Methodology.

[22]  Sean Pinney,et al.  Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  Heather J Ross,et al.  Clinical Differences Between Continuous Flow Ventricular Assist Devices: A Comparison Between HeartMate II and HeartWare HVAD , 2013, Journal of cardiac surgery.

[24]  Nader Moazami,et al.  The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  G. Thomas,et al.  Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics. , 2012, Biochemical and biophysical research communications.

[26]  Priya Sharma,et al.  Incidence and management of gastrointestinal bleeding with continuous flow assist devices. , 2012, The Annals of thoracic surgery.

[27]  Z. Ge,et al.  Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. , 2011, Gastroenterology.

[28]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[29]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[30]  D. Lüdecke,et al.  Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment , 2008, Neurological research.

[31]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[32]  Kenneth C. Anderson,et al.  Thalidomide and lenalidomide: Mechanism-based potential drug combinations , 2008, Leukemia & lymphoma.

[33]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .

[34]  Jun.  Octreotide , 1989, The Lancet.